Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells.

@article{Gebauer2000CisplatinresistanceIT,
  title={Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells.},
  author={Gerhard Gebauer and Beloo Mirakhur and Quang Lam Nguyen and Scott K Shore and Henry Simpkins and Nishanthi Dhanasekaran},
  journal={International journal of oncology},
  year={2000},
  volume={16 2},
  pages={321-5}
}
Cisplatin has been widely used as a chemotherapeutic agent to treat different types of tumors. However, its use is limited by the ability of the tumor cells to develop cisplatin-resistance. The molecular lesion that produces cisplatin-resistance is poorly understood. In this report, we show that cisplatin activates a robust apoptotic pathway involving the activation of JNK and p38MAPK whereas it fails to elicit such a response in cisplatin-resistant 2008/C13 cells. Analysis of the defective… CONTINUE READING